ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1640

Physical Function and Performance in SLE: A Comparison of Two Population-Based Cohorts

Jessica Fitzpatrick1, Mrinalini Dey2, C. Barrett Bowling3, S. Sam Lim4, Courtney Hoge5, Charmayne Dunlop-Thomas5, Maria Dall'Era6, Patti Katz7, Jinoos Yazdany1 and Laura Plantinga8, 1UCSF, San Francisco, CA, 2Centre for Rheumatic Diseases, King's College London, London, United Kingdom, 3Duke University, Durham, NC, 4Emory University School of Medicine, Atlanta, GA, 5Emory University, Atlanta, GA, 6Division of Rheumatology, University of California, San Francisco, CA, 7UCSF, San Rafael, CA, 8University of California, San Francisco, San Francisco, CA

Meeting: ACR Convergence 2025

Keywords: Aging, Cohort Study, physical function, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1633–1649) ARP Posters II: ARP Epidemiology & Public Health

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Physical function and performance are top priorities to individuals with systemic lupus erythematosus (SLE). Suboptimal physical function and performance are associated with disability, loss of independence, and mortality, but disparities in physical function and performance remain poorly understood. We leveraged data from two large population-based cohorts to compare self-reported physical function and measured physical performance across two U.S. populations of individuals with SLE.

Methods: Approaches to Positive, Patient-centered Experiences of Aging with Lupus (APPEAL) participants were recruited from the Georgians Organized Against Lupus (GOAL) cohort for a one-time study visit (10/2019–5/2022). California Lupus Epidemiology Study (CLUES) participants were from the third wave of ongoing data collection (1/2018–9/2019). Participants were included in this analysis if they had complete data for both the Short Physical Performance Battery (SPPB; score range: 0–12) and PROMIS Physical Function 10a/10b (CLUES/APPEAL; T-scores for both). Additional variables included age, sex, race/ethnicity, BMI, measures of SLE activity [Systemic Lupus Activity Questionnaire (SLAQ)] and damage [Brief Index of Lupus Damage (BILD)], disease duration, and depression (CLUES: Patient Health Questionnaire (PHQ)-8; APPEAL: PROMIS Depression Short Form 8b). Demographic and clinical characteristics were examined by cohort. The associations of cohort membership with physical function and physical performance were estimated using multivariable linear regression.

Results: Mean age was similar in APPEAL (N&#3f446) and CLUES (N&#3f173; 46 vs 45 years) and both cohorts were predominantly female (APPEAL 92% vs. CLUES 90%; Table 1). However, the APPEAL cohort was primarily Black (81%), whereas CLUES included a higher proportion of Asian (41%), White (28%), and Hispanic (23%) participants. Lupus disease activity and damage were higher among APPEAL participants (SLAQ: 9 vs. 14; BILD: 3 vs. 2). Self-reported physical function was lower among APPEAL compared to CLUES participants, with mean T scores of 41.5 and 47.9, respectively, as was measured physical performance (Figure 1), with 60% having an SPPB score < 10 (vs. 46% in CLUES). After adjustment for age and sex, physical function T-scores were 0.64 SD (6.4 points) lower among APPEAL compared to CLUES participants (Table 2). This association, however, was no longer statistically significant after adjustment for clinical factors. Further adjustment for race did not substantively change the association between cohort membership and physical function. Similar relationships were observed for SPPB scores (Table 2).

Conclusion: Despite similar age and sex distributions, participants in the APPEAL cohort had significantly lower physical function and performance compared to those in the CLUES cohort. Importantly, these differences were largely explained by clinical characteristics, particularly disease activity, and not by differences in race/ethnicity between the cohorts. Because SLE activity is potentially reversible, targeted interventions to reduce disease activity may help mitigate disparities in physical function and performance.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: J. Fitzpatrick: None; M. Dey: None; C. Bowling: None; S. Lim: Accordant, 2, AstraZeneca, 2, Biogen, 5, BMS, 5, Genentech, 2, Gilead, 5, GSK, 2, Novartis, 5, UCB, 5; C. Hoge: None; C. Dunlop-Thomas: None; M. Dall'Era: AstraZeneca, 2, Aurinia, 2, Biogen, 2, Genentech, Inc., 2, GlaxoSmithKline (GSK), 2, Janssen, 2; P. Katz: None; J. Yazdany: AstraZeneca, 2, Aurinia, 5, Gilead, 5; L. Plantinga: None.

To cite this abstract in AMA style:

Fitzpatrick J, Dey M, Bowling C, Lim S, Hoge C, Dunlop-Thomas C, Dall'Era M, Katz P, Yazdany J, Plantinga L. Physical Function and Performance in SLE: A Comparison of Two Population-Based Cohorts [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/physical-function-and-performance-in-sle-a-comparison-of-two-population-based-cohorts/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/physical-function-and-performance-in-sle-a-comparison-of-two-population-based-cohorts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology